Dicerna Posts Mixed Nedosiran Data In Rare Kidney Disease Trial
- Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) has announced top-line results from its PHYOX4 study of nedosiran for primary hyperoxaluria type 3 (PH3).
- Related: Why Is Dicerna Stock Getting Slammed Today?
- Nedosiran demonstrated safety and tolerability results consistent with previously reported studies.
- Patients administered nedosiran also showed a trend in urinary oxalate (Uox) reduction; however, these reductions did not meet prespecified secondary efficacy endpoint criteria.
- Dicerna plans to submit an FDA marketing application for nedosiran to treat PH1 in Q4 of 2021.
- No subjects in either group achieved the prespecified secondary efficacy endpoint, a greater than 30% decrease from baseline in 24-hour Uox excretion on at least two consecutive visits over the three-month observation period.
- However, all patients administered a single dose of nedosiran demonstrated Uox reductions relative to baseline at one or more time points during the three months.
- Primary hyperoxaluria (PH) is a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys.
- Price Action: DRNA shares are up 1.73% at $21.15 during the market session on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: BriefsBiotech News Health Care Small Cap Movers Trading Ideas General
